![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lunglife Ai Inc | LSE:LLAI | London | Ordinary Share | ORD USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -0.69% | 14.40 | 13.80 | 15.00 | 14.50 | 14.40 | 14.50 | 19,886 | 09:42:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLLAI
RNS Number : 1544L
LungLife AI, INC
11 May 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Result of Annual General Meeting
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting , held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a poll.
The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:
Resolution Votes for % Votes against % Votes withheld Resolution 1 ( Common ) TO receive the Annual Report and Accounts of the Company for the year ended 31 December 2021 together with the directors' and auditor's reports thereon. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 2 ( Common ) THAT Roy Davis be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 3 ( Common ) THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 4 ( Common ) THAT David Anderson be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 5 ( Common ) THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 6 ( Common ) THAT Sara Barrington be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 7 ( Common ) THAT James McCullough be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- --------------- Resolution 8 ( Common ) THAT Crowe LLP be, and hereby is, reappointed as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. 14,321,090 100 0 0 0 ----------- ---- -------------- ---------------
As at 11 May 2022 , there were 25,480,270 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO Via Walbrook PR David Anderson, CFO Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970 & Broker) Daniel Adams / Virginia Bull / Cameron MacRitchie Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 / Marriage 0 7867 984 082
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGEALSFFFKAEFA
(END) Dow Jones Newswires
May 11, 2022 10:17 ET (14:17 GMT)
1 Year Lunglife Ai Chart |
1 Month Lunglife Ai Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions